Globus Medical, Inc.

Filing receipts

“Cost of Sales Three Months Ended March 31, Change (In thousands, except percentages) 2026 2025 $ % Cost of sales (exclusive of amortization of intangibles) $ 234,066 $ 195,397 $ 38,669 19.8 % Percentage of net sales 30.8 % 32.7 % The $38.7 million, or 19.8%, increase in cost of sales for the three months ended March 31, 2026 was primarily driven by the cost of sales from Nevro products of $26.2 million, an increase in product cost of $4.0 million driven primarily by higher volume, and an increase in freight cost of $4.0 million.”

“31 Table of Cont ents Amortization of Intangibles Three Months Ended March 31, Change (In thousands, except percentages) 2026 2025 $ % Amortization of intangibles $ 29,526 $ 28,802 $ 724 2.5 % Percentage of net sales 3.9 % 4.8 % Amortization of intangibles increased by $0.7 million, or 2.5%, primarily driven by the acquisition of intangibles in connection with the Nevro Merger contributing $1.7 million in expense, partially offset by the finalization of amortization of other intangible assets as compared to the three months ended March 31, 2025.”

“Other Income/(Expense), Net Three Months Ended March 31, Change (In thousands, except percentages) 2026 2025 $ % Other income/(expense), net $ 5,568 $ 6,664 $ (1,096) (16.4 %) Percentage of net sales 0.7 % 1.1 % Other income/(expense) decreased by $1.1 million, or 16.4%, primarily due to $2.1 million of foreign currency loss in the current period compared to a $4.3 million gain in the same period of the prior year.”